FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine. Invention discloses novel inducible chimeric cytokine receptors which are sensitive to a certain ligand, for example a small molecule or a protein. Receptors according to the present invention can be used to improve the functional activity of genetically modified T-cells.
EFFECT: receptor-modified T-cells according to the present invention can be used in medical practice for immunotherapy of a wide range of diseases, in particular in treating oncological diseases.
96 cl, 45 dwg, 2 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| CHIMERIC PROTEIN | 2016 |
|
RU2746755C2 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN 12 AND METHODS OF USE THEREOF | 2019 |
|
RU2826183C2 |
| ACTIVATED POLYPEPTIDES OF INTERLEUKIN-2 AND METHODS OF USE THEREOF | 2019 |
|
RU2826454C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
